IR-News

AUSSENDER



Biofrontera AG
Ansprechpartner: Investor Relations
Tel.: +49 (0) 214 87 63 20
E-Mail: ir@biofrontera.com

FRüHERE MELDUNGEN

WEITERE IR-NEWS

07.07.2022 - 18:30 | Kontron AG
07.07.2022 - 18:00 | Talenthouse AG
07.07.2022 - 17:50 | Heidelberger Beteiligungsholding AG
pta20220513053
Business news for the stock market

Biofrontera AG: First quarter conference call to be held on May 19, 2022


Leverkusen, Germany (pta053/13.05.2022/18:20) - Biofrontera AG (Frankfurt Stock Exchange: B8F, US-OTC: BFAGY), an international biopharmaceutical company, will be releasing its financial results for the first quarter 2022 on Tuesday, May 17, 2022.

The Management Board of Biofrontera AG will provide information on the key developments in the reporting period in a conference call on Thursday, May 19, 2022.

The conference call for shareholders and interested investors will start in German at 10:00 a.m., in English at 2:00 p.m.

In German, May 19, 2022 at 10:00 am CEST (4:00 am ET)

Dial-in number Germany: +49 69 201744210

Conference code: 50069038#

In English, May 19, 2022 at 2:00 pm CEST (8:00 am ET)

Dial-in number USA: +1 8774230830

Dial-in number UK: +44 2030092470

Conference code: 38990475#

Please dial in 10 minutes ahead of time to ensure a timely start of the conference call.

-End-

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin. Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on US OTC market (BFAGY). www.biofrontera.com

(end)
emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE0006046113 (share)
other stock exchanges: US OTC
|
|
98.695 Abonnenten
|
201.036 Meldungen
|
83.116 Pressefotos

BUSINESS

07.07.2022 - 16:40 | Financial Planning Standards Board Deutschland e.V.
07.07.2022 - 12:20 | SRH AlsterResearch AG
07.07.2022 - 11:55 | SRH AlsterResearch AG
07.07.2022 - 11:45 | pressetext.redaktion
07.07.2022 - 09:30 | DeepSec GmbH
Top